1. Best-Selling Cancer Drugs,
Top 10
Best-Selling Cancer Drugs,
Q1–Q3, 2017
Source: GEN – Genetic Engineering & Biotechnology News г.

2. Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017
Trade Name/INN
Indication
Q1–Q3 sales 2017
Q1–Q3 sales 2016
% Change
 1. Revlimid® (lenalidomide)
Multiple myeloma, in combination with dexamethasone; multiple myeloma, as a maintenance therapy following autologous hematopoietic stem cell transplantation; transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities; mantle cell lymphoma in patients whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.
$5.999 billion
$5.166 billion
 16, 1 %
2. Rituxan® (rituximab, MabThera)
 Non-Hodgkin lymphoma; chronic lymphocytic leukemia; rheumatoid arthritis (RA) in combination with methotrexate in adult patients with moderately to severely active RA who have inadequate response to one or more TNF-antagonist therapies; granulomatosis with polyangiitis (GPA) (Wegener’s granulomatosis), and microscopic polyangiitis (MPA) in adults in combination with glucocorticoids
$5.760 billion
$5.620 billion
2.5%
3. Herceptin (trastuzumab)
HER2-overexpressing breast cancer; HER2-overexpressing metastatic gastric or gastroesophageal-junction adenocarcinoma
$5.363 billion
$5.252 billion
2.1%
4. Avastin (bevacizumab)
Metastatic colorectal cancer, nonsquamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, cervical cancer, as well as recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
$5.121 billion
$5.241 billion
-2.3% г.

3. Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 (2)
Trade Name/INN
Indication
Q1–Q3 sales 2017
Q1–Q3 sales 2016
% Change
5. Neulasta/Peglasta (pegfilgrastim) and Neupogen/Gran (filgrastim)
Both Neulasta and Neupogen decrease the incidence of infection—as manifested by febrile neutropenia—in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia; and increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome or acute radiation syndrome).
$3.864 billion, consisting of $3.420 billion for Neulasta (Amgen), $423 million for Neupogen (Amgen), and ¥2.4 billion ($ million) combined (Kyowa Hakko Kirin)
$4.151 billion, consisting of $3.532 billion for Neulasta (Amgen), $592 million for Neupogen (Amgen), and ¥3.1 billion ($ million) combined (Kyowa Hakko Kirin)
-6.9%
6. Opdivo (nivolumab)
Melanoma, metastatic non-small cell lung cancer (NSCLC), advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, colorectal cancer, and hepatocellular carcinoma
$3.587 billion
$2.464 billion
45.6%
7. Imbruvica® (ibrutinib)
Adults with mantle cell lymphoma who have received at least one prior therapy; chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL); CLL/SLL with 17p deletion; Waldenström’s macroglobulinemia; Marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy; Chronic graft-versus-host disease after failure of one or more lines of systemic therapy
$3.236 billion
$2.226 billion
45.4%
8. Keytruda® (pembrolizumab)
Melanoma, non-small cell lung cancer, head and neck squamous cell cancer, classical Hodgkin Lymphoma, urothelial carcinoma, microsatellite instability-high cancer, and gastric cancer
$2.512 billion
$919 million
173.3%

4. Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017 (3)
Trade Name/INN
Indication
Q1–Q3 sales 2017
Q1–Q3 sales 2016
% Change
9. Ibrance® (palbociclib)
Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women; or fulvestrant in women with disease progression following endocrine therapy
$2.410 billion
$1.492 billion
61.5%
10. Velcade® (bortezomib)
Multiple myeloma, mantle cell lymphoma
$1.780 billion
$1.876 billion
-5.1%